Friday 6 November 2026 Export AMRX’s income statement to Excel — free account

AMNEAL PHARMACEUTICALS, INC.

AMRX Healthcare Drug Manufacturers Specialty & Generic

AMNEAL PHARMACEUTICALS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 billion, up 8.05% from fiscal 2024.

Revenue: +9.96%
EPS: +267.0%
Free cash flow: −50.9%
Total debt: +23.8%

Quarter to September 2026, against a year earlier

Revenue growth 5 yrs

19.41 0.54 −2.71%

Follow AMRX

Alert me

Market cap: $6.8B
P/E: 36.9×
Fwd P/E: 44.2×
Dividend yield: —
F-score: 7/9
Altman Z: 1.94
Beneish M: −2.68
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

AMNEAL PHARMACEUTICALS, INC. (AMRX) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2025: revenue by segment, and margins
Affordable Medicines	1,746	57.82%
AvKARE	745	24.67%
Specialty	529	17.51%
Gross margin		36.88%
Operating margin		13.05%
Pre-tax margin		4.61%

Revenue by segment $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Affordable Medicines	1,746 57.82%	1,685 60.32%	1,471 61.47%	1,432 64.73%	1,366 65.26%	1,343 67.41%	1,309 80.48%	1,439 86.53%	1,034 100.00%	1,018 100.00%
AvKARE	745 24.67%	663 23.73%	532 22.22%	406 18.36%	349 16.67%	294 14.74%	0 0.00%	0 0.00%	—	—
Specialty	529 17.51%	446 15.95%	390 16.31%	374 16.91%	378 18.07%	356 17.85%	318 19.52%	224 13.47%	—	0 0.00%
Specialty	—	—	—	—	—	356 17.85%	318 19.52%	224 13.47%	—	—
Eliminations	—	—	—	—	—	(356) (17.85%)	(318) (19.52%)	(224) (13.47%)	—	—
Revenue	3,019	2,794	2,394	2,212	2,094	1,993	1,626	1,663	1,034	1,018

Operating income by segment $m, and margin

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Affordable Medicines	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Specialty	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
AvKARE	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Specialty	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Corporate and other	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Operating income	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

Revenue by region $m

Line	FY2019	FY2018	FY2017
United States	1,603 98.56%	1,603 96.39%	947 91.58%
Non-US	21 1.27%	60 3.59%	75 7.21%
Other, not broken out	—	—	13 1.21%
Revenue	1,626	1,663	1,034

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.